GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy
Abstract Lipid nanoparticles have demonstrated utility in hepatic delivery of a range of therapeutic modalities and typically deliver their cargo via low-density lipoprotein receptor-mediated endocytosis. For patients lacking sufficient low-density lipoprotein receptor activity, such as those with h...
Main Authors: | Lisa N. Kasiewicz, Souvik Biswas, Aaron Beach, Huilan Ren, Chaitali Dutta, Anne Marie Mazzola, Ellen Rohde, Alexandra Chadwick, Christopher Cheng, Sara P. Garcia, Sowmya Iyer, Yuri Matsumoto, Amit V. Khera, Kiran Musunuru, Sekar Kathiresan, Padma Malyala, Kallanthottathil G. Rajeev, Andrew M. Bellinger |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-05-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-023-37465-1 |
Similar Items
-
The Gal/GalNac lectin as a possible acetylcholine receptor in Entamoeba histolytica
by: Marisol Pacheco-Sánchez, et al.
Published: (2023-05-01) -
Evidence of gene conversion in genes encoding the Gal/GalNac lectin complex of Entamoeba.
by: Gareth D Weedall, et al.
Published: (2011-06-01) -
Role of GalNAc4S-6ST in astrocytic tumor progression.
by: Tatsuya Kobayashi, et al.
Published: (2013-01-01) -
Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer
by: Eugenia Fernandez, et al.
Published: (2021-11-01) -
ERK8 is a negative regulator of O-GalNAc glycosylation and cell migration
by: Joanne Chia, et al.
Published: (2014-03-01)